ClinicalTrials.gg
CompletedNCT00419341Updated Jan 25, 2013Results posted

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

A Phase 3 interventional study of Human Normal Immunoglobulin for Subcutaneous Administration in Primary Immune Deficiency, sponsored by CSL Behring. Completed at 13 sites in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-25.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.

Enrollment
Largest of 13
49 · median 25
Started
2006
the only one that year
Phase 3
9 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one has the largest enrollment of the 13 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 3, and was the 3rd registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Primary Immunodeficiency Diseases by CSL Limited as a file.
02

Study summary

The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).

Read the detailed description

The entire study consists of a 12-week wash-in/wash-out period followed by a 12-month treatment period. Pharmacokinetic (PK) parameters were assessed in a sub-group of subjects.

03

Conditions studied

  • Primary Immune Deficiency

Keywords

  • Immune globulin subcutaneous
  • SCIG
  • Primary immunodeficiency
  • PID
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 2 to 75 years
  • Subjects with primary humoral immunodeficiency, namely with a diagnosis of: CVID (Common Variable Immunodeficiency) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or XLA (X-linked Agammaglobulinemia)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Newly diagnosed PID
  • Evidence of an active serious infection at the time of screening (i.e., but not limited to: bacteremia/septicemia, pneumonia, fungal osteomyelitis)
  • of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma
  • Known hyperprolinemia
  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria
  • Allergic reactions to immunoglobulins or other blood products
  • Known antibodies to Immunoglobulin A (IgA)
  • The subject is receiving (oral and parenteral, daily ≥ 0.15 mg of prednisone equivalent/kg/day) or other systemic
  • Female who is pregnant, breast feeding or planning a pregnancy during the course of the study
  • Participation in a study with an product other than (IVIG) within 1 month prior to enrollment
  • A positive result at screening on any of the following viral markers: (HIV), virus (HCV) and virus (HBV)
  • (ASAT) or Alanine aminotransferase (ALAT) concentration > 2.5 times the upper normal limit (UNL)
  • Creatinine concentration > 1.5 times the UNL
  • Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    IgPro20

    Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.

    Biological: Human Normal Immunoglobulin for Subcutaneous Administration

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)

    The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  2. Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)

    Evaluate non-inferiority of steady-state IgG area under the concentration-time curves standardized to a 7-day period (sAUCs) for subcutaneous immunoglobulin (SCIG) (IgPro20) versus the sAUC under intravenous immunoglobulin (IVIG) (Privigen) treatment. The sAUC under IVIG was taken from the same subjects in a preceding study (either ZLB03_002CR \[NCT00168025\] or ZLB05_006CR \[NCT00322556\]).

    Time frame: Measured during a single dosing interval after at least 12 weeks of stable subcutaneous (SC) dosing with IgPro20 treatment

Secondary outcomes

  1. Annualized Rate of Clinically Documented SBIs (ITT Population)

    The annualized rate was based on the total number of SBIs and the total number of subject study days during the study for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.

    Time frame: For the duration of the study, up to 15 months

  2. Annualized Rate of Clinically Documented SBIs (PPE Population)

    The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  3. Annualized Rate of Infection Episodes

    The annualized rate was based on the total number of infection episodes occurring during the efficacy period (N = 96) divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: Efficacy period: up to 12 months (week 13 to completion visit)

  4. Number of Infection Episodes (Serious and Non-serious)

    Total number of infections for the specified analysis population

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  5. Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections

    The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection (N = 71), and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  6. Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections

    Total number of days out of work / school / kindergarten / day care or unable to perform normal daily activities due to infections, for the specified analysis population

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  7. Annualized Rate of Hospitalization Due to Infection

    The annualized rate was based on the total number of days of hospitalization due to infection (N = 7) and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  8. Number of Days of Hospitalization Due to Infections

    Total number of days of hospitalization due to infections for the specified analysis population

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  9. Use of Antibiotics for Infection Prophylaxis and Treatment

    Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.

    Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)

  10. Total Serum IgG Trough Levels

    The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.

    Time frame: Every 4 weeks, throughout the 12-month efficacy period

  11. Maximum Concentration (Cmax) of Total Serum IgG at Steady State

    Time frame: Week 28 ± 1 week of the treatment period

  12. Tmax at Steady State

    Timepoint of maximum concentration (Cmax)

    Time frame: Week 28 ± 1 week of the treatment period

Other outcomes

  1. Minimum Concentration (Cmin) of Total Serum IgG at Steady State

    Time frame: Week 28 ± 1 week of the treatment period

  2. Rate of All AEs by Relatedness and Seriousness

    The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.

    Time frame: For the duration of the study, up to 15 months

  3. Rate of Mild, Moderate, or Severe Local Reactions

    In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of injection site reaction, injection site bruising, infusion site scab, injection site cyst, injection site eczema, injection site irritation, injection site nodule, and injection site pain. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

    Time frame: For the duration of the study, up to 15 months

07

Results

Posted Jan 25, 2013

Participant flow

A total of 12 centers in the United States enrolled subjects for this study.

Wash in/Wash Out Period
Participant flow — Wash in/Wash Out Period
MilestoneIgPro20
Started49
Completed38
Not completed11
Withdrew: Withdrawal by subject8
Withdrew: Adverse event2
Withdrew: Disqualifying laboratory results1
Efficacy Period
Participant flow — Efficacy Period
MilestoneIgPro20
Started38
Completed28
Not completed10
Withdrew: Withdrawal by subject6
Withdrew: Protocol violation1
Withdrew: Lost to follow-up1
Withdrew: Non-compliance1
Withdrew: Termination of study site1

Outcome measures

PrimaryAnnualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)

The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · SBIs per subject year
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)
SBIs per subject yearIgPro20
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)0.00
PrimaryArea Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)

Evaluate non-inferiority of steady-state IgG area under the concentration-time curves standardized to a 7-day period (sAUCs) for subcutaneous immunoglobulin (SCIG) (IgPro20) versus the sAUC under intravenous immunoglobulin (IVIG) (Privigen) treatment. The sAUC under IVIG was taken from the same subjects in a preceding study (either ZLB03_002CR \[NCT00168025\] or ZLB05_006CR \[NCT00322556\]).

Time frame:
Measured during a single dosing interval after at least 12 weeks of stable subcutaneous (SC) dosing with IgPro20 treatment
Reported as:
Mean · days*g/L
Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)
days*g/LIgPro20 (PK Substudy)IVIG (Privigen; Previous Study)
Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)105.6 ± 31.56103.2 ± 20.00
Statistical analysis
  • IgPro20 (PK Substudy) vs IVIG (Privigen; Previous Study) · t-test, 2 sided · Geometric mean ratio (gmr): 1.002 · 90% CI 0.951 to 1.055Geometric mean ratio SCIG:IVIG non-inferiority was concluded if the lower GMR confidence limit was 0.8 or more
SecondaryAnnualized Rate of Clinically Documented SBIs (ITT Population)

The annualized rate was based on the total number of SBIs and the total number of subject study days during the study for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.

Time frame:
For the duration of the study, up to 15 months
Reported as:
Number · SBIs per subject year
Annualized Rate of Clinically Documented SBIs (ITT Population)
SBIs per subject yearIgPro20
Annualized Rate of Clinically Documented SBIs (ITT Population)0.00
SecondaryAnnualized Rate of Clinically Documented SBIs (PPE Population)

The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · SBIs per subject year
Annualized Rate of Clinically Documented SBIs (PPE Population)
SBIs per subject yearIgPro20
Annualized Rate of Clinically Documented SBIs (PPE Population)0.00
SecondaryAnnualized Rate of Infection Episodes

The annualized rate was based on the total number of infection episodes occurring during the efficacy period (N = 96) divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
Efficacy period: up to 12 months (week 13 to completion visit)
Reported as:
Number · infection episodes per subject year
Annualized Rate of Infection Episodes
infection episodes per subject yearIgPro20
Annualized Rate of Infection Episodes2.76 (2.235 to 3.370)
SecondaryNumber of Infection Episodes (Serious and Non-serious)

Total number of infections for the specified analysis population

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · infections
Number of Infection Episodes (Serious and Non-serious)
infectionsIgPro20
Number of Infection Episodes (Serious and Non-serious)96
SecondaryAnnualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections

The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection (N = 71), and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · days per subject year
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections
days per subject yearIgPro20
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections2.06
SecondaryNumber of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections

Total number of days out of work / school / kindergarten / day care or unable to perform normal daily activities due to infections, for the specified analysis population

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · days
Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections
daysIgPro20
Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections71
SecondaryAnnualized Rate of Hospitalization Due to Infection

The annualized rate was based on the total number of days of hospitalization due to infection (N = 7) and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · days per subject year
Annualized Rate of Hospitalization Due to Infection
days per subject yearIgPro20
Annualized Rate of Hospitalization Due to Infection0.20 (0 to 7)
SecondaryNumber of Days of Hospitalization Due to Infections

Total number of days of hospitalization due to infections for the specified analysis population

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · days
Number of Days of Hospitalization Due to Infections
daysIgPro20
Number of Days of Hospitalization Due to Infections7
SecondaryUse of Antibiotics for Infection Prophylaxis and Treatment

Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.

Time frame:
Efficacy period: up to 12 months (week 13 to the completion visit)
Reported as:
Number · days per subject year
Use of Antibiotics for Infection Prophylaxis and Treatment
days per subject yearIgPro20
Use of Antibiotics for Infection Prophylaxis and Treatment48.52
SecondaryTotal Serum IgG Trough Levels

The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.

Time frame:
Every 4 weeks, throughout the 12-month efficacy period
Reported as:
Mean · g/L
Total Serum IgG Trough Levels
g/LIgPro20
Total Serum IgG Trough Levels12.53 ± 3.21
SecondaryMaximum Concentration (Cmax) of Total Serum IgG at Steady State
Time frame:
Week 28 ± 1 week of the treatment period
Reported as:
Mean · g/L
Maximum Concentration (Cmax) of Total Serum IgG at Steady State
g/LIgPro20 (PK Substudy)
Maximum Concentration (Cmax) of Total Serum IgG at Steady State16.16 ± 4.93
SecondaryTmax at Steady State

Timepoint of maximum concentration (Cmax)

Time frame:
Week 28 ± 1 week of the treatment period
Reported as:
Median · days
Tmax at Steady State
daysIgPro20 (PK Substudy)
Tmax at Steady State3.118 ± 1.7729
Other pre-specifiedMinimum Concentration (Cmin) of Total Serum IgG at Steady State
Time frame:
Week 28 ± 1 week of the treatment period
Reported as:
Mean · g/L
Minimum Concentration (Cmin) of Total Serum IgG at Steady State
g/LIgPro20 (PK Substudy)
Minimum Concentration (Cmin) of Total Serum IgG at Steady State13.70 ± 4.39
Other pre-specifiedRate of All AEs by Relatedness and Seriousness

The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.

Time frame:
For the duration of the study, up to 15 months
Reported as:
Number · AEs per infusion
Rate of All AEs by Relatedness and Seriousness
AEs per infusionIgPro20
All0.773
At least possibly related0.634
Serious0.004
At least possibly related and serious0
Other pre-specifiedRate of Mild, Moderate, or Severe Local Reactions

In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of injection site reaction, injection site bruising, infusion site scab, injection site cyst, injection site eczema, injection site irritation, injection site nodule, and injection site pain. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

Time frame:
For the duration of the study, up to 15 months
Reported as:
Number · local reactions per infusion
Rate of Mild, Moderate, or Severe Local Reactions
local reactions per infusionIgPro20
All0.592
Mild0.553
Moderate0.038
Severe0.002

Adverse events

Collected over Approximately 15 months (including the 3 month wash in/wash out period and the 12 month efficacy period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20—7/49 (14.3%)49/49 (100%)
Most frequent serious events
Most frequent serious events
EventIgPro20
Chest painGeneral disorders2/49
GastroenteritisInfections and infestations1/49
Small intestinal obstructionGastrointestinal disorders1/49
Tooth abscessInfections and infestations1/49
CellulitisInfections and infestations1/49
Urinary tract infectionInfections and infestations1/49
Haemoglobin decreasedInvestigations1/49
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders1/49
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/49
Most frequent other events
Showing 10 of 32
Most frequent other events
EventIgPro20
Injection site reactionGeneral disorders49/49
SinusitisInfections and infestations14/49
HeadacheNervous system disorders13/49
NasopharyngitisInfections and infestations11/49
CoughRespiratory, thoracic and mediastinal disorders8/49
DiarrhoeaGastrointestinal disorders7/49
BronchitisInfections and infestations6/49
FatigueGeneral disorders6/49
Abdominal pain upperGastrointestinal disorders5/49
Acute sinusitisInfections and infestations5/49

Baseline characteristics

Age Continuous
Age Continuous(years)IgPro20
Mean34.4 ± 20.09
Age, Customized
Age, Customized(participants)IgPro20
2 to < 12 years3
12 to < 16 years7
16 to < 65 years33
≥ 65 years6
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20
Female27
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IgPro20
Black or African American3
White46
Type of Primary Immunodeficiency
Type of Primary Immunodeficiency(participants)IgPro20
Common variable immunodeficiency (CVID)46 ± 21.24
X-linked agammaglobulinemia (XLA)3
08

Study locations

13 sites
  • Study Site
    Los Angeles, California 90025, United States
  • Study Site
    Los Angeles, California 90027, United States
  • Study Site
    Centennial, Colorado 80112, United States
  • Study Site
    North Palm Beach, Florida 33408, United States
  • Study Site
    Atlanta, Georgia 30322, United States
  • Study Site
    Fort Wayne, Indiana 46815, United States
  • Study Site
    Indianapolis, Indiana 46202, United States
  • Study Site
    Iowa City, Iowa 52242, United States
  • Study Site
    St.Louis, Missouri 63104-1095, United States
  • Study Site
    Newark, New Jersey 07103, United States
  • Study Site
    New York, New York 10029, United States
  • Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Study Site
    Dallas, Texas 75230, United States
09

References and documents

Publications

  • Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, Orange JS. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8. PubMed 20454851 ↗
  • Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000. PubMed 21553933 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2006
First posted
Jan 8, 2007
Start
Nov 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jan 25, 2013
Last update
Jan 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00419341
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jan 8, 2007
Start date
Nov 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jan 25, 2013
Last update
Jan 25, 2013

Study contacts

Richard L. Wasserman, MD, PhD
principal investigator · Dallas Allergy Immunology and Medical City Children's Hospital,
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hizentra

Start the discussion